Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1879 - BET inhibitors induce apoptosis through ATAD2 suppression in AR positive triple negative breast cancer cells (12P)


18 Nov 2017


Poster lunch


Cancer Biology




Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652


H. YANG1, S.H. Shim2, K.S. Lee2, I.H. Park1

Author affiliations

  • 1 Translational Cancer Research Branch, Division Of Cancer Biology, Research Institute, National Cancer Center, 10408 - Gyeonggi-do/KR
  • 2 Center For Breast Cancer, National Cancer Center Hospital,, National Cancer Center, 10408 - Gyeonggi-do/KR


Abstract 1879


Triple negative breast cancer (TNBC) is a heterogeneous disease entity with inferior outcomes to those of other subtypes. The androgen receptor (AR) is present in up to 30% of patients with TNBC.


In this study, we investigated the effect of bromodomain inhibitor (BETi), JQ1 combined with AR targeted therapy in AR positive TNBC. The activity of enzalutamide, anti-androgen drug was moderate with IC50 >10μM even in AR strong positive MDA-MB-453 TNBC cell line. JQ1 demonstrated significant anti-tumor activity in TNBC cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-20) and IC50 values were in 0.2-0.3μM range.


JQ1 induced apoptosis in a dose-dependent manner, evidenced by increased levels of cleaved caspase 3, caspase 9, and PARP. Further, JQ1 treatment induced G0-G1 arrest and downregulation of cyclin E1 and cyclin A2. The treatment of JQ1 reduced cell viability synergistically when combined with enzalutamide in AR expressing TNBC cell lines. After JQ1 treatment, MYC expression had significantly reduced over 72 hrs. In addition, ATAD2, a conserved factor harboring both ATPase domain and a bromodomain, expression levels were significantly repressed with JQ1 treatment in both cell lines. Suppression of ATAD2 was more significant when JQ1 was treated in siRNA of AR treated TNBC cells.


Taken together, our study showed that BET inhibitor with AR targeting strategy is a promising new therapeutic option for AR positive TNBC. Further studies including in vivo analysis is planned.

Clinical trial identification

not applicable

Legal entity responsible for the study

In Hae Park




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.